|
|
|
| Effect of aerosol inhalation of Broncho-Vaxom combined with beClomethasone Propionate Aerosol in the treatment of children with acute attack of bronchial asthma |
| WU Xiaoxu |
| Department of Paediatrics, West China-Guang′an Hospital, Sichuan University, Sichuan Province, Guang′an 638000, China |
|
|
|
Abstract Objective To explore the effect of Broncho-Vaxom combined with inhalation of valproate on serum levels of galectin-3 (Gal-3) and serum amyloid A (SAA) in treating children with acute attack of bronchial asthma. Methods From January 2014 to September 2017, 120 children with bronchial asthma treated by paediatrics in West China-Guang′an Hospital, Sichuan University were selected as subjects. According to the random number table method, they were divided into the study group and the control group, with 60 children in each group. The control group was given Beclomethasone Propionate Aerosol inhalation treatment, while the study group was given Broncho-Vaxom combined treatment on the basis of the control group. The clinical efficacy, pulmonary function, serum inflammatory factors and levels of Gal-3, SAA and adverse reactions were analyzed. Results The total effective rate of treatment in the study group was higher than that in the control group, the difference was highly statistically significant (P < 0.05). After treatment, the levels of forced expiratory volume in 1 s (FEV1) and γ-interferon (INF-γ) in both groups were increased, and the levels of FEV1, PEF and INF-γ in the study group were higher than those in the control group, the differences were highly statistically significant (P < 0.05). The levels of IL-4, Gal-3 and SAA in the study group were significantly decreased, the differences were highly statistically significant (P < 0.05). There were no serious adverse reactions during the course of treatment in both groups. Conclusion The implementation of Broncho-Vaxom combined with inhalation of Beclomethasone Propionate Aerosol can effectively improve the pulmonary function of children with bronchial asthma, reduce the levels of Gal-3 and SAA, release the inflammation injury and improve airway remodeling.
|
|
|
|
|
|
[1] Aldubi HM，Alissa EM，Kamfar HZ，et al. Bronchial asthma and hypovitaminosis D in Saudi children [J]. Asia Pac Allergy 2015，5（2）：103-113.
[2] 潘凌宇，韩燕全，柳清，等.气道重塑与磷脂酰肌醇3激酶/蛋白激酶B信号通路在支气管哮喘发病机制中的研究进展[J].安徽医药，2016，20（12）：2214-2218.
[3] 樊英，康淑红.抗喘利肺汤联合西药治疗小儿哮喘临床研究[J].陕西中医，2018，39（11）：116-119.
[4] Galanakis P，Gaga M，Psarros F，et al. Effectiveness of omalizumab in Greek patients with severe allergic asthma （SAA）：The SMILE study [J]. Eur Respir J，2016，48（suppl 60）：PA3380.
[5] 杨绍雪，叶柳青，雷涵.血清淀粉样蛋白A在支气管哮喘诊治中的临床价值[J].全科医学临床与教育，2017，15（5）：522-524.
[6] 陈乐，苏雯，俞善昌，等.雾化吸入丙酸倍氯米松混悬液治疗儿童轻中度哮喘急性发作有效性及安全性研究[J].中国实用儿科杂志，2015，30（8）：601-604.
[7] 中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南（2016年版）[J].中华结核和呼吸杂志，2016，39（9）：675-697.
[8] 中华医学会呼吸病学分会哮喘学组.支气管哮喘控制的中国专家共识[J].中华内科杂志，2013，52（5）：440-443.
[9] 邹艳萍，罗小兰，刘利.布地奈德与丙酸倍氯米松辅助特布他林雾化吸入治疗小儿哮喘急性发作的对比研究[J].中国药房，2016，27（17）：2388-2391.
[10] 曹建，阳永珍，罗天勇.泛福舒对支气管哮喘急性发作患者Th1/Th2细胞平衡及临床症状的影响[J].临床肺科杂志，2016，21（12）：2255-2258.
[11] 吕燕青，詹平，谷红梅，等.泛福舒胶囊辅治儿童支气管哮喘疗效及其对细胞免疫和炎性因子的影响[J].疑难病杂志，2016，15（11）：1170-1173.
[12] Ather JL，Karina C，Rebecca M，et al. Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice [J]. J Immunol，2011，187（1）：64-73.
[13] 吕燕华，袁小玲，缪卓峰，等.血清淀粉样蛋白A在支气管哮喘急性发作中的应用价值[J].实用医学杂志，2016，32（11）：1771-1773.
[14] 范艳平，易甲其，吴敏.支气管哮喘患儿血清MMP-9，Gal-3和TGF-β1与肺功能的关系研究[J].现代检验医学杂志，2017，32（4）：76-79.
[15] 黄小龙.血清及痰液MMP、TIMP及TNF-α与支气管哮喘患者气道重塑的关系[J].实用临床医药杂志，2016， 20（1）：52-55.
[16] 徐继尧，马科，寇艳，等.妥布特罗联合丙酸倍氯米松混悬液雾化吸入治疗儿童中度哮喘急性发作临床研究[J].中国妇幼保健，2018，33（14）：3232-3234.
[17] 杨勇，宋俊杉，张环，等.泛福舒胶囊联合参麦注射液治疗儿童支气管哮喘的疗效及对血清IL-4、hs-CRP、Ang-2的影响[J].现代生物医学进展，2018，18（6）：1133-1136，1019.
[18] 周晓，谢永伟.特布他林与丙酸倍氯米松联合雾化吸入治疗哮喘急性发作期患者的临床效果[J].中国医药，2018，13（3）：376-379.
[19] 蔡亲武，杨子江，王昌乐.布地奈德或丙酸倍氯米松联合特布他林治疗小儿轻中度哮喘急性发作的疗效和安全性比较[J].中国药房，2017，28（24）：3368-3371.
[20] 雷勇，秦大妮，鲍莉，等.小剂量依托红霉素对哮喘患儿急性发作肺功能及血清Gal-3、TGF-β1水平的影响[J].临床肺科杂志，2017，6（12）：2171-2174. |
|
|
|
